Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer

Blohmer, JU; Gore, M.; Küemmel, Sherko; Verheijen, R; Massuger, Leon F.A.G.; Bois, Andreas du; Smit, Willem M.; Kaye, Stan B.; Deubelbeiss, C.

doi:10.1200/jco.2005.23.16_suppl.2534

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies do not show evidence of clinical benefit in advanced stages diseases [21]. On the other hand, several authors have reported the use of mAb against this receptor, such as cetuximab [22], matuzumab [23] and panitumomab [24], with modest results that did not exceed the expectation of the international medical community in comparison with established therapy for this stage of the disease.…”

Section: Resultsmentioning

confidence: 98%

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

Ruiz-Lorente¹,

Sayly²,

Santiesteban³

et al. 2021

JCT

View full text Add to dashboard Cite

Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF®, the humanized mAb nimotuzumab or the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with a more than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9%; 1.1% and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months for CIMAvax-EGF®, nimotuzumab and the combination of both, respectively. Thus fulfilling the hypothesis of safety and efficacy proposed in the investigation was achieved. The three therapeutic regimens achieved overall survival rates greater than

show abstract

Section: Resultsmentioning

confidence: 98%

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

Ruiz-Lorente¹,

Sayly²,

Santiesteban³

et al. 2021

JCT

View full text Add to dashboard Cite

show abstract

“…3 The mechanisms that predict which patients will respond to cetuximab have yielded interesting, albeit incomplete results. 3 There have been several clinical trials administering EGFR inhibitors to women with advanced cervical carcinoma with response rates of 0% to 5% when administered as a single agent [26][27][28][29][30] and 12% to 32% when administered in combination with chemotherapy 31,32 with no additional benefit in a randomized trial in combination with carboplatin and paclitaxel. 33 Importantly, citing the early activity of cetuximab in head and neck cancer, several published trials have treated patients with LACC with concomitant radiation, cisplatin, and EGFR inhibitors.…”

Section: Discussionmentioning

confidence: 99%

An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer

Fracasso¹,

Duska

Thaker

et al. 2022

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives: This study explored the feasibility of cetuximab with chemoradiation in women with cervical carcinoma and evaluated fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) to assess early response to cetuximab (NCT00292955). Patients and Methods: Eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVB invasive carcinoma of the uterine cervix were treated on 1 of 3 dose levels (DL). DL1 consisted of neoadjuvant cetuximab, then concurrent radiotherapy with cetuximab 250 mg/m2/cisplatin 40 mg/m2, followed by weekly cetuximab. DL2 consisted of radiotherapy with cetuximab 200 mg/m2 and cisplatin 30 mg/m2. DL3 consisted of radiotherapy with cetuximab 250 mg/m2 and cisplatin 30 mg/m2. Patients underwent 18F-FDG-PET/CT before treatment, after neoadjuvant cetuximab, and at the end of treatment. Results: Of the 21 patients enrolled, 9, 3, and 9 were treated in DL1, DL2, and DL3, respectively. DL1 required dose reductions due to gastrointestinal toxicities. DL2 and 3 were tolerated with 1 dose-limiting toxicity (grade 4 renal failure) at DL3. Following 3 weekly treatments of neoadjuvant cetuximab in DL1, 7 patients had maximum standardized uptake value changes on 18F-FDG-PET/CT consistent with response to cetuximab. Of the 12 patients with locally advanced disease, eleven evaluable patients had no evidence of disease on 18F-FDG-PET/CT at treatment end. Five-year progression-free survival and overall survival rates for all patients were 57.5% and 58.5%, respectively. Conclusions: Cetuximab with cisplatin 30 mg/m2 and radiotherapy was tolerated. 18F-FDG-PET/CT demonstrated early evidence of response to neoadjuvant cetuximab. With advances in precision oncology and the recent approval of pembrolizumab in metastatic cervical cancer, dual-target inhibition with an epidermal growth factor receptor inhibitor may be a promising treatment in the future.

show abstract

“…These included pertuzumab, a Her-2 dimerisation inhibitor [24]; siplizumab, an anti-CD2 antibody [25]; metazumab [26] and panitumomab [27], both anti-EGFR antibodies; SGN-30, an anti-CD30 chimeric antibody [28]; SGN-40, a humanised anti-CD40 antibody [29,30]; and more encouraging reports with MDX-010, which blocks the immune inhibitory cytotoxic T lymphocyte antigen-4 ligand, with dacarbazine in melanoma [31] and alone in renal cell cancer [32]. …”

Section: Other Antibodiesmentioning

confidence: 99%

American Society of Clinical Oncology 41st Annual Meeting

Dillman

2005

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

For many years the annual meeting of the American Society of Clinical Oncology (ASCO) has been the premier meeting in clinical oncology, and one that is closely scrutinised by Wall Street and international investors because of the economic significance of cancer therapies to the pharmaceutical and biotechnology industries. The area of biologicals and targeted therapies exploded in the late 1990s after the blockbuster results with the monoclonal antibody rituximab in the treatment of lymphoma. Although historically a somewhat conservative organisation that is still closely tied to classical cytotoxic chemotherapy, ASCO has been able to integrate various areas of biological therapy into its scope of clinical activity. Although ASCO still has 'American' in its title, it is really the 'International' Society of Clinical Oncology, as reflected by the attendance at this year's meeting by approximately 30,000, with approximately two-thirds attending from outside the US. There were 9708 abstracts published in conjunction with the meeting, 86 of which are referenced in this review. There were 10 papers chosen for plenary presentations and many other key papers were presented at other oral abstract sessions and poster discussion session that were organised by tumour type. In addition to key papers submitted by specific tumour type, for this year's meeting there were 103 abstracts published in the session entitled 'Developmental Therapeutics: Immunotherapy', and 218 in the session entitled Developmental Therapeutics: Molecular Targets', for a total of 321 biological therapy abstracts compared with only 125 abstracts for the session entitled 'Developmental Therapeutics: Cytotoxic Therapy'. This meeting review is organised by biotherapy modality rather than tumour type.

show abstract

Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer

Cited by 8 publications

References 0 publications

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer

American Society of Clinical Oncology 41st Annual Meeting

Contact Info

Product

Resources

About

Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer

Cited by 8 publications

References 0 publications

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF&lt;sup&gt;&amp;reg;&lt;/sup&gt; Therapeutic Vaccine

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF&lt;sup&gt;&amp;reg;&lt;/sup&gt; Therapeutic Vaccine

An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer

American Society of Clinical Oncology 41st Annual Meeting

Contact Info

Product

Resources

About

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>®</sup> Therapeutic Vaccine

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>®</sup> Therapeutic Vaccine